

Resource Summary Report

Generated by ASWG on Aug 9, 2026

CD11b-APC, human and mouse

RRID:AB_2654646

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-109-364, RRID:AB_2654646

Antibody Information

URL: http://antibodyregistry.org/AB_2654646

Proper Citation: Miltenyi Biotec Cat# 130-109-364, RRID:AB_2654646

Target Antigen: CD11b

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 2-2018; Target Distribution myeloid cells, NK cells, microglia, lymphocytes, monocytes, macrophages; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-802. (RRID:AB_2726324).

Antibody Name: CD11b-APC, human and mouse

Description: This monoclonal targets CD11b

Target Organism: mouse, human

Clone ID: REA592

Antibody ID: AB_2654646

Vendor: Miltenyi Biotec

Catalog Number: 130-109-364

Record Creation Time: 20250819T213439+0000

Record Last Update: 20250819T232432+0000

Ratings and Alerts

No rating or validation information has been found for CD11b-APC, human and mouse.

Warning: Discontinued: 2021

Discontinued: 2-2018; Target Distribution myeloid cells, NK cells, microglia, lymphocytes, monocytes, macrophages; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-802. (RRID:AB_2726324).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Zhou Z, et al. (2024) Rebalancing TGF- β /PGE2 breaks RT-induced immunosuppressive barriers by enhancing tumor-infiltrated dendritic cell homing. International journal of biological sciences, 20(1), 367.

Tilsed CM, et al. (2022) CD4⁺ T cells drive an inflammatory, TNF- α /IFN-rich tumor microenvironment responsive to chemotherapy. Cell reports, 41(13), 111874.